These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26789526)

  • 1. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: A pooled analysis of 18 randomized controlled trials.
    Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
    Int J Cancer; 2016 Jun; 138(11):2771-3. PubMed ID: 26789526
    [No Abstract]   [Full Text] [Related]  

  • 2. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
    Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
    Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter to the editor.
    Sterrantino C; Miroddi M; Phillips B; Stewart L
    Int J Cancer; 2016 Jun; 138(11):2763-70. PubMed ID: 26789636
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis.
    Wang L; Chen YZ; Shi D; Shi XY; Zou Z; Zhao JH
    Drugs R D; 2011 Dec; 11(4):317-26. PubMed ID: 22133387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infections following chemotherapies of the newer generation.
    Junghanss C
    Haematologica; 2005 Dec; 90(12):1591. PubMed ID: 16330430
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies.
    Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S9-19. PubMed ID: 21843103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review.
    Baas JM; Krens LL; Guchelaar HJ; Ouwerkerk J; de Jong FA; Lavrijsen AP; Gelderblom H
    Cancer Treat Rev; 2012 Aug; 38(5):505-14. PubMed ID: 22100458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
    Zhou JX; Feng LJ; Zhang X
    Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis.
    Zhang D; Ye J; Xu T; Xiong B
    J Chemother; 2013 Jun; 25(3):170-5. PubMed ID: 23783142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors.
    Deeken JF; Shimkus B; Liem A; Hill D; Gurtler J; Berghorn E; Townes L; Lu H; Trifan O; Zhang S
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1473-83. PubMed ID: 23589315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
    Costa R; Carneiro BA; Agulnik M; Rademaker AW; Pai SG; Villaflor VM; Cristofanilli M; Sosman JA; Giles FJ
    Oncotarget; 2017 Jan; 8(5):8910-8920. PubMed ID: 27852042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnesium: are we better off without it?
    Pantano F; Vincenzi B; Santini D; Tonini G
    Anticancer Drugs; 2013 Oct; 24(9):879-80. PubMed ID: 23884107
    [No Abstract]   [Full Text] [Related]  

  • 15. Pre-medications for cetuximab induced infusion reactions - commentary.
    McKibbin T; Donald Harvey R; Saba NF
    Oral Oncol; 2014 Dec; 50(12):e71. PubMed ID: 25223595
    [No Abstract]   [Full Text] [Related]  

  • 16. Does cetuximab cause small bowel perforation?
    Ozturk MA; Eren OO; Oyan B
    J BUON; 2014; 19(3):865. PubMed ID: 25261682
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to: 'Pre-medications for cetuximab induced infusion reactions - commentary'.
    Adkins D; Ley J
    Oral Oncol; 2014 Dec; 50(12):e72. PubMed ID: 25282254
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.
    Lo JA; Fisher DE; Flaherty KT
    JAMA Oncol; 2015 Dec; 1(9):1340-1. PubMed ID: 26270186
    [No Abstract]   [Full Text] [Related]  

  • 19. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.
    Pujol JL; Pirker R; Lynch TJ; Butts CA; Rosell R; Shepherd FA; Vansteenkiste J; O'Byrne KJ; de Blas B; Heighway J; von Heydebreck A; Thatcher N
    Lung Cancer; 2014 Feb; 83(2):211-8. PubMed ID: 24332319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of toxicity associated with chemotherapy for breast cancer].
    Mukohara T; Mukai H
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():516-22. PubMed ID: 17682204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.